SFRP5 correlates with obesity and metabolic syndrome and increases after weight loss in children.
Secreted frizzled-related protein 5 (SFRP5) is a novel anti-inflammatory adipokine, which has been shown as a mediator between obesity and its comorbidities. The aim of this study was to evaluate the associations of SFRP5 with metabolic syndrome (MetS) and the effects of lifestyle interventions on circulating SFRP5 levels in children. A cross-sectional study was conducted among 111 obese children and 49 lean controls, and a lifestyle intervention was performed in a subgroup of 31 obese children for 6 months. Anthropometric parameters, clinical data and circulating SFRP5 levels were measured at baseline and after lifestyle intervention. Secreted frizzled-related protein 5 was significantly lower in obese children, especially in those with MetS, and negatively correlated with body mass index (BMI), waist circumference and homeostasis model assessment of insulin resistance. Independent of other well-known risk factors, SFRP5 was a significant predictor of MetS in children. In the longitudinal study, lifestyle intervention led to significant weight loss and higher SFRP5 levels. Furthermore, changes in BMI significantly correlated with the rising magnitude of SFRP5. Serum SFRP5 is regulated by weight status and seems to be correlated with metabolic disorders in children.